Publications by authors named "Munehiro Matsumoto"

Article Synopsis
  • * This study included 127 severe asthma patients to assess ACO prevalence using specific criteria, comparing outcomes between those with and without ACO.
  • * ACO was found in 31.5% of severe asthma patients, but it did not significantly impact the rates of exacerbations or the annual decline in lung function over the study period.
View Article and Find Full Text PDF

Introduction: Notably, few studies have evaluated the recent changes in the prevalence of allergic diseases in young adults. Studies examining the risk of allergy in two populations with similar social backgrounds, other than the region in which they live, are rare.

Methods: First-year students from Hokkaido University were enrolled in this study between 2011 and 2019.

View Article and Find Full Text PDF

Background: Real-time asthma exacerbation prediction and acute asthma attack detection are essential for patients with severe asthma. Peak expiratory flow (PEF) exhibits a potential for use in long-term asthma self-monitoring. However, the method for processing PEF calculations remains to be clarified.

View Article and Find Full Text PDF
Article Synopsis
  • AIM plays a significant role in the development and progression of chronic obstructive pulmonary disease (COPD) by increasing levels of matrix metalloprotease-12 (MMP-12), which leads to lung inflammation and damage.
  • In studies using mouse models and in vitro experiments, researchers found that mice lacking AIM showed reduced lung damage and inflammation, as well as lower MMP-12 levels compared to normal mice.
  • The study also revealed that patients with COPD have a higher blood AIM/IgM ratio, which correlates with disease severity and increased risk of COPD exacerbations and mortality.
View Article and Find Full Text PDF

Background: There are knowledge gaps in the potential role of Club cell 16-kDa secretory protein (CC16) in severe asthma phenotypes and type 2 inflammation, as well as the longitudinal effect of CC16 on pulmonary function tests and exacerbation risk in epidemiological studies.

Objective And Methods: To assess whether serum CC16 is associated with eosinophilic inflammation in patients with severe asthma. We also examined the effect of this protein on the annual decline in forced expiratory volume in the first second (FEV) and the risk of exacerbation using a longitudinal approach.

View Article and Find Full Text PDF

Immunomodulators (tocilizumab/baricitinib) improve outcomes of coronavirus disease 2019 (COVID-19) patients, but the synergistic effect of remdesivir is unknown. The effect of combination therapy with remdesivir, immunomodulators, and standard treatment in COVID-19 patients was investigated. This retrospective, single-center study included COVID-19 patients who were treated with tocilizumab or baricitinib.

View Article and Find Full Text PDF

Pulmonary artery agenesis (PAA) is a rare congenital vascular anomaly usually diagnosed during infancy. We herein report a 67-year-old man with PAA manifesting as massive hemoptysis. Contrast-enhanced computed tomography of the chest revealed the diagnosis of PAA, which we speculated to have resulted in the present event.

View Article and Find Full Text PDF

Introduction: Club cell secretory protein-16 (CC16) is a major anti-inflammatory protein expressed in the airway; however, the potential role of CC16 on overweight/obese asthma has not been assessed. In this study, we examined whether obesity reduces airway/circulatory CC16 levels using experimental and epidemiological studies. Then, we explored the mediatory role of CC16 in the relationship of overweight/obesity with clinical asthma measures.

View Article and Find Full Text PDF
Article Synopsis
  • Tocilizumab and baricitinib have been found to help improve outcomes for COVID-19 patients, but a direct comparison of their effectiveness had not been done until this study.
  • A retrospective study conducted at Hokkaido University Hospital analyzed data from 98 COVID-19 patients who received either drug, revealing no significant differences in all-cause mortality or respiratory improvement after 28 days of treatment.
  • Key factors influencing patient outcomes included age and chronic renal disease, while patient treatment with either drug showed similar rates of secondary infections, suggesting both could be equally effective in treating COVID-19.
View Article and Find Full Text PDF

Background: The chitinase-like protein YKL-40 is associated with airflow limitation on spirometry and airway remodeling in patients with asthma. It remains unclear whether YKL-40 is associated with morphologic changes in the airways and parenchyma or with future progression of airflow limitation in severe asthma.

Objective: To evaluate the association of circulating YKL-40 levels with morphologic changes in the airways and parenchyma and with longitudinal progression of airflow limitation.

View Article and Find Full Text PDF

We present three cases with an atypical clinical course of organizing pneumonia (OP) secondary to coronavirus disease 2019 (COVID-19). Three patients were discharged with satisfactory improvement after standard steroid therapy for COVID-19. Shortly after the completion of treatment, the patients experienced a flare-up of symptoms.

View Article and Find Full Text PDF

Background: No clinical scoring system has yet been established to estimate the likelihood of coronavirus disease (COVID-19) and determine the suitability of diagnostic testing in suspected COVID-19 patients.

Methods: This was a single-center, retrospective, observational study of patients with suspected COVID-19 and confirmed COVID-19. Patient background, clinical course, laboratory and computed tomography (CT) findings, and the presence of alternative diagnoses were evaluated.

View Article and Find Full Text PDF

Background: We recently reported that severe asthma patients with frequent exacerbations showed high blood eosinophil counts (Eo) and fractions of exhaled nitric oxide (FeNO) compared with non-exacerbators. However, we did not determine exact cutoff values related to exacerbation. The aim of this study was to determine the cutoff values of Eo and FeNO that could be related to the exacerbation of severe asthma.

View Article and Find Full Text PDF

Background: Until now, the prevalence of macrolide-resistant Mycoplasma pneumoniae (MP) infection among adult patients has been low, and severe MP pneumonia due to a macrolide-resistant strain has seldom been reported. Here, we describe a rare case of severe life-threatening MP pneumonia due to a macrolide-resistant strain in an adult, which was finally treated with fluoroquinolone and tetracycline after failed treatment with macrolide and corticosteroid.

Case Presentation: A 39-year-old apparently healthy woman complained of fever and productive cough.

View Article and Find Full Text PDF

Background: Previous studies have shown the association of anthropometric measures with poor asthma symptoms, especially among women. However, the potential influence of visceral adiposity on asthma symptoms has not been investigated well.

Objective: In this study, we have evaluated whether visceral adiposity is related to poor adult asthma symptoms independent of anthropometric measures and sex.

View Article and Find Full Text PDF

Background: The coexistence of asthma and allergic rhinitis (AR) and its distinct association with obesity have been reported. However, few studies have differentiated the two types of AR, i.e.

View Article and Find Full Text PDF

Azole antifungals are used not only clinically for fungal infections but also used as agricultural fungicides. Recently, azole-resistant Aspergillus fumigatus containing a tandem repeat in the promoter region of cyp51A combined with amino acid substitution(s) appears in the environment in Eurasia, especially in several European countries. Although azole fungicides have been used in Japan, especially in Hokkaido, surveillance and characterization of A.

View Article and Find Full Text PDF